PFE (Pfizer, Inc.)

PFE (Pfizer, Inc.)

• Entry Price: $16.07
• Risk Level:8
• Profitability Level: 7
• 1year Target Price: $20-$25

Having settled the 1996 Trovan clinical study case with the Kano State government in Nigeria, Pfizer can move forward to other developing drugs. Pfizer Inc (NYSE: PFE), together with Medivation, Inc. (NASDAQ: MDVN) has started the initiation of a Phase 3 trial of the investigational drug Dimebon (Latrepirdine) in patients with Huntington disease. In addition, the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to Dimebon for the treatment of Huntington disease.

On January 26, 2009 Pfizer and Wyeth entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction. The conglomerate company will create one of the most diversified companies in the global health care industry, with product offerings in numerous growing therapeutic areas, a strong product pipeline, and leading scientific and manufacturing capabilities.

Yahoo analysts estimate growth for the following year to be 13.8%; 3.8% over the industry’s projected growth, making Pfizer a hot stock to buy.

We wish you luck on your investments and as always do your own research prior to purchasing or selling a stock. We make recommendations based on our own research and this site is solely for the purpose of entertainment reading. Thank you for visiting Hot Stocks to Buy.

MRK - MERCK, Inc.

MRK (MERCK, Inc)

• Entry Price: $30.02
• Risk Level: 8
• Profitability Level: 7
• 1year Target Price: $35-$40

Despite all the legal troubles surrounding Merck’s Vioxx drug, the company is still going strong with other marketable drugs. On July 31, 2009 the U.S. Food and Drug Administration (FDA) approved and expanded the use for ISENTRESS®. ISENTRESS can now be used in the treatment of adult patients starting HIV-1 therapy for the first time (treatment-naïve), as well as in treatment-experienced adult patients. ISENTRESS is used in combination with other antiretroviral (ARV) medicines for the treatment of HIV-1 infection in adult patients.

With the announcement of Merck & Co.’s head of vaccine retirement effective Nov. 1 2009, this could be beneficial to the company considering it has been plagued by management decisions that lead to manufacturing deficiencies cited by the Food and Drug Administration which reduced sales significantly. During March 2009 Merck unanimously approved a $41.1 billion acquisition of partner drug maker Schering-Plough Corp. of Kenilworth, N.J. This merger will lead to cost-cutting and give Merck a better edge over the drug industry.

With a cost-cutting merger on the way and reorganization at the management level to come, analysts at Yahoo Finance still estimate a profit margin of 24.59% and 5.0% earnings for the next year making Merck hot stock to buy with a mid to high level of risks.

We wish you luck on your investments and as always do your own research prior to purchasing or selling a stock. We make recommendations based on our own research and this site is solely for the purpose of entertainment reading. Thank you for visiting Hot Stocks to Buy.

MGM - MGM Mirage

[MGM] MGM Mirage - Hot Stocks to Buy Entry Price $7.90

• Risk level: 6
• Profit potential: 9
• Price Target 6 months: $14 - $16
• Price Target 12 months: $28 - $30
• We expect MGM to outperform in the near and long term

MGM Mirage, through its subsidiaries, owns and operates casino resorts in the United States. The company’s resorts offer gaming, hotel, dining, entertainment, retail, and other resort amenities. It also owns and operates golf courses and a golf club.

We have selected MGM Mirage as a hot stock to buy canidate due to the potential profit it represents in both the short and long term. With the recent turnaround in the overall stock market and gaming market, MGM is poised for continued price increase. The following highlights are reasons we have selected MGM Mirage as a hot stocks to buy stock.

• MGM Mirage will eventually see the CityCenter project come to a completion by December 2009 according to the latest Associated Press report “MGM Mirage and Dubai World each agreed to fund their remaining payments for CityCenter with letters of credit, and the lenders agreed to immediately fund $1.8 billion to finish the project, rather than wait until each partner had fully paid its share. The company said CityCenter is now on track to be open by December 2009, with the Harmon Hotel & Spa opening in 2010.”
• It looks like the bankruptcy rumors have subsided with the announcement of the CityCenter agreement with Dubai.
• According to Yahoo’s insider transaction report there has not been any recent insider selling into the recent stock runup from a low of $1.88 to it’s current price of $7.96.
• We expect increased travel to Las Vegas as an alternative option due to the recent swine flu scare. This is good for MGM and all other gaming casinos.
• Earnings on May 4th should be inline or better as estimates have been lowered.

Hot Stocks to Buy recommends taking a small holding in MGM stock at it’s current price.  The profit potential of the stock is great and the risk is moderate.  Overall MGM looks like a hot buy anywhere beloww $10.

We wish you luck on your investments and as always do your own research prior to purchasing or selling a stock. We make recommendations based on our own research and this site is solely for the purpose of entertainment reading. Thank you for visiting Hot Stocks to Buy.